Home >> Pharmaceuticals >> Food & Beverage >>

Cellerant Therapeutics, Inc. - Product Pipeline Review - 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 23 | Code: MRS - 18301

Cellerant Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Cellerant Therapeutics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Cellerant Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cellerant Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cellerant Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cellerant Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Cellerant Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Cellerant Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cellerant Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cellerant Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cellerant Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellerant Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cellerant Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Cellerant Therapeutics, Inc. Snapshot 4
Cellerant Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Cellerant Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Cellerant Therapeutics, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Cellerant Therapeutics, Inc. - Pipeline Products Glance 9
Cellerant Therapeutics, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Cellerant Therapeutics, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Cellerant Therapeutics, Inc. - Drug Profiles 13
romyelocel-L 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
CLT-009 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Antibody to Target Cancer Stem Cell for Cancer 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Cellerant Therapeutics, Inc. - Pipeline Analysis 16
Cellerant Therapeutics, Inc. - Pipeline Products by Route of Administration 16
Cellerant Therapeutics, Inc. - Pipeline Products by Molecule Type 17
Cellerant Therapeutics, Inc. - Recent Pipeline Updates 18
Cellerant Therapeutics, Inc. - Dormant Projects 20
Cellerant Therapeutics, Inc. - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 22
Disclaimer 23

List of Tables
Cellerant Therapeutics, Inc., Key Information 4
Cellerant Therapeutics, Inc., Key Facts 4
Cellerant Therapeutics, Inc. - Pipeline by Indication, 2015 6
Cellerant Therapeutics, Inc. - Pipeline by Stage of Development, 2015 7
Cellerant Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 8
Cellerant Therapeutics, Inc. - Phase II, 2015 9
Cellerant Therapeutics, Inc. - Phase I, 2015 10
Cellerant Therapeutics, Inc. - Preclinical, 2015 11
Cellerant Therapeutics, Inc. - Discovery, 2015 12
Cellerant Therapeutics, Inc. - Pipeline by Route of Administration, 2015 16
Cellerant Therapeutics, Inc. - Pipeline by Molecule Type, 2015 17
Cellerant Therapeutics, Inc. - Recent Pipeline Updates, 2015 18
Cellerant Therapeutics, Inc. - Dormant Developmental Projects,2015 20

List of Figures
Cellerant Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 6
Cellerant Therapeutics, Inc. - Pipeline by Stage of Development, 2015 7
Cellerant Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 8
Cellerant Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015 16
Cellerant Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 17

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing